Mediclinic International plc Bond Placement at Hirslanden (9304N)
February 04 2021 - 1:00AM
UK Regulatory
TIDMMDC
RNS Number : 9304N
Mediclinic International plc
04 February 2021
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" , the " Company ", or the "Group" )
4 February 2021
SUCCESSFUL BOND PLACEMENT AT HIRSLANDEN
Mediclinic International plc, the diversified international
private healthcare services group, announces that its Swiss
division, Hirslanden, has successfully completed the placement of a
CHF145m fixed-rate bond at a coupon of 1.25%. The payment date is
25 February 2021 with a five-year term. The bond will be listed on
the SIX Swiss Exchange. UBS Investment Bank and Zürcher
Kantonalbank acted as joint lead managers.
Proceeds from the issue will be used to redeem the maturing
CHF145m bond issued on 25 February 2015 with a coupon of 1.625%.
The successful refinancing enables Hirslanden to lower its interest
expense and to extend its debt maturity profile.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare
services group, established in South Africa in 1983, with divisions
in Switzerland, Southern Africa (South Africa and Namibia) and the
UAE.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
At 30 September 2020, Mediclinic comprised 76 hospitals, eight
sub-acute and specialised hospitals, 17 day case clinics and 18
outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 800 inpatient beds;
Mediclinic Southern Africa operations included 52 hospitals (three
of which in Namibia), eight sub-acute and specialised hospitals and
11 day case clinics (four of which operated by Intercare) across
South Africa, and more than 8 700 inpatient beds; and Mediclinic
Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In
addition, under management contracts, Mediclinic Middle East
operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The divisions' contributions to Group revenue for the financial
year ended 31 March 2020 were 47% by Hirslanden, 29% by Mediclinic
Southern Africa and 24% by Mediclinic Middle East.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address : 6(th) Floor, 65 Gresham Street, London,
EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker : Morgan Stanley & Co International plc and
UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of
FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IODEAXADESPFEFA
(END) Dow Jones Newswires
February 04, 2021 02:00 ET (07:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2023 to Apr 2024